Previous 10 | Next 10 |
Gainers: [[VOXX]] +42.9%. [[IRIX]] +22.0%. [[PXLW]] +11.8%. [[QTRX]] +7.9%. [[GNMK]] +6.9%.Losers: [[RDHL]] -9.4%. [[LINC]] -6.1%. [[LMND]] -5.3%. [[APM]] -3.9%. [[REVG]] -3.6%. For further details see: VOXX, IRIX, RDHL and LINC among after-hours movers
RedHill Biopharma (RDHL) entered into an underwriting agreement with H.C. Wainwright wherein the underwriter agreed to purchase on a firm commitment basis 1.28M ADSs at $7.84/ADS.Underwriters granted 30-day option to purchase up to additional 191,326 ADSs at the public offering price.Each ADS...
RedHill Biopharma Announces $10 Million Bought Deal Offering PR Newswire TEL AVIV, Israel and RALEIGH, N.C. , Jan. 11, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today an...
RedHill Biopharma's (RDHL) partner Cosmo Pharmaceuticals has completed their Phase 2 Proof-of-Concept trial evaluating rifamycin SV-MMX 600mg in patients with diarrhea-predominant irritable bowel syndrome (IBS-D).As part of an exclusive license agreement between RedHill and Cosmo from October...
RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D Canada NewsWire TEL AVIV, Israel and RALEIGH, N.C ,, Jan. 11, 2021 /CNW/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or "the Company"),...
The FDA has designated Fast Track status to RedHill Biopharma's (RDHL) RHB-204 as a potential first-line, stand-alone, oral treatment of pulmonary nontuberculous mycobacteria ((NTM)) disease caused by Mycobacterium avium Complex.Recently, the treatment was granted Orphan Drug tag, e...
RedHill Biopharma's RHB-204 Granted FDA Fast Track Designation for NTM Disease U.S. Phase 3 study underway to evaluate RHB-204 as a first-line, stand-alone, oral treatment for pulmonary NTM disease - a rare condition with no FDA-approved first-line therapy FDA Fast Track des...
RedHill Biopharma ([[RDHL]] +3.2% announces preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms.The study aimed to evaluate s...
RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differenc...
Following a second independent Data Safety Monitoring Board (DSMB) safety review, RedHill Biopharma ([[RDHL]] +0.1%) has received a second unanimous recommendation to continue its global Phase 2/3 study testing Opaganib in hospitalized patients with severe COVID-19 pneumonia.Th...
News, Short Squeeze, Breakout and More Instantly...
Redhill Biopharma Ltd. Company Name:
RDHL Stock Symbol:
NASDAQ Market:
Redhill Biopharma Ltd. Website:
RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien PR Newswire TEL-AVIV, Israel and RALEIGH, NC , July 22, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biophar...
RedHill Biopharma Terminates License Agreement for Aemcolo® PR Newswire TEL-AVIV, Israel and RALEIGH, NC , July 9, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today ...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...